<DOC>
	<DOCNO>NCT01217775</DOCNO>
	<brief_summary>The objective study evaluate effectiveness safety double-blind , randomize , placebo-controlled clinical trial self administer PH80 intranasal spray acute management cycle relate symptom woman regularly experience premenstrual dysphoric disorder ( PMDD ) .</brief_summary>
	<brief_title>Intranasal PH80 Spray Acute Management Symptoms Premenstrual Dysphoric Disorder</brief_title>
	<detailed_description>Premenstrual disorder characterize negative mood , behavioral , physical symptom occur consistently several day two week menses , disrupt normal functioning , subside postmenstrual phase cycle . Marked irritability , mark depressed mood , mark anxiety , overeat specific food craving , mood swing , lack energy , pain among common symptom moderate severe premenstrual disorder . It estimate 75 % woman reproductive age ( menarche perimenopause ) experience physical behavioral symptom premenstrually 40 % woman symptom intense ( moderate severe ) require medical attention . For 3-8 % woman premenstrual symptom severe enough interfere work interpersonal relationship . Premenstrual Dysphoric Disorder ( PMDD ) define Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSM-IV ) research criterion , represent severe disable end premenstrual disorder spectrum . For woman severe premenstrual symptom PMDD , symptoms bothersome enough produce impact psychological and/or occupational functioning , professional attention require . Selective serotonin reuptake inhibitor ( SSRIs ) fluoxetine , sertaline paroxetine approve United States Food Drug Administration ( FDA ) chronic treatment PMDD , however use SSRIs significantly increase risk suicide adolescent young adult . Antidepressants also associate significant relapse short long term treatment PMDD . Contraceptives also prescribe treat moderate severe premenstrual symptom , besides severe adverse effect ( drospirenone ethinyl estradiol ) treatment choice woman willing become pregnant . Pherin Pharmaceuticals synthesize number pherines screen biologic activity vitro . PH80 pherine show bind subset peripheral receptor nasal chemosensory neuron . Pherines PH80 think exert activity rapid stimulation hypothalamus , require systemic uptake distribution . PH80 investigate potential treatment woman suffer cycle relate symptom Premenstrual Dysphoric Disorder . Each single administration PH80 test study deliver similar amount PH80 ( 800 nanogram ) nasal passage find previous investigation ( Pherin Clinical Study # PH80 CL003 , # PH80 CL015 # PH80 CL016 ) improve premenstrual symptom PMDD patient administer intranasally acute basis .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<criteria>Female , age 18 43 year , regular menstrual cycle 22 35 day length inclusive . Women childbearing potential may participate pregnant breast feeding , agree use one follow method contraception throughout study : abstinence , intrauterine device , condom foam , diaphragm spermicide , vasectomy spermicide , tubal ligation spermicide , oral contraceptive barrier method . Women use oral contraceptive must stable dose regimen least 6 month prior study entry must agree continue dose regimen throughout phase study . Patients report least 1year history regularly experience PMDD . Patients able read understand Informed Consent document ; willing able comply protocol ; read , understood , voluntarily sign write Informed Consent prior performance studyspecific procedure . Patients fail meet study criterion PMDD Patients active diabetes mellitus , neurological , cardiac , renal , hepatic , pulmonary disease , significant medical gynecological abnormality condition , determine physical examination and/or clinical laboratory test . Patients diagnose Major Depressive Disorder Bipolar Depression . Patients acute chronic condition judgment clinical Investigator could harm patient and/or alter outcome study . Additional clinical examination symptom assessment perform time determine continue eligibility study participation . Patients use intranasal medication study drug within 14 day prior study entry and/or RunIn and/or Treatment Phases study . Patients clinical condition disease , take concomitant medication , clinical judgment Investigator could place patient undue risk , interfere study participation , confound result study . Patients current last 2 year history substance abuse . Patients positive urine drug screen follow : amphetamine , barbiturate , cocaine metabolite , opiate , benzodiazepine , and/or cannabinoids . Patients treat previously PH80 . Patients participate another research study receive another investigational drug within 30 day prior study entry study . Patients use exclusionary prescription and/or nonprescription medication specify study protocol ( described report ) within 14 day prior study entry and/or RunIn and/or Treatment Phases study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>PMDD , Premenstrual , Dysphoria , Mood Swings , Bloating .</keyword>
</DOC>